[go: up one dir, main page]

WO2008139947A1 - 下痢の予防又は治療剤 - Google Patents

下痢の予防又は治療剤 Download PDF

Info

Publication number
WO2008139947A1
WO2008139947A1 PCT/JP2008/058328 JP2008058328W WO2008139947A1 WO 2008139947 A1 WO2008139947 A1 WO 2008139947A1 JP 2008058328 W JP2008058328 W JP 2008058328W WO 2008139947 A1 WO2008139947 A1 WO 2008139947A1
Authority
WO
WIPO (PCT)
Prior art keywords
glu
cys
val
gly
amino acid
Prior art date
Application number
PCT/JP2008/058328
Other languages
English (en)
French (fr)
Inventor
Junya Yoneda
Tetsuo Yano
Yukie Seki
Yuzuru Eto
Yusuke Amino
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Priority to EP08752258.7A priority Critical patent/EP2156846B1/en
Priority to JP2009514106A priority patent/JP5321452B2/ja
Priority to ES08752258.7T priority patent/ES2499015T3/es
Publication of WO2008139947A1 publication Critical patent/WO2008139947A1/ja
Priority to US12/613,727 priority patent/US20100105864A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　カルシウム受容体活性化作用を有する化合物、例えばγ－Ｇｌｕ－Ｘ－Ｇｌｙ（Ｘはアミノ酸又はアミノ酸誘導体を表す）、γ－Ｇｌｕ－Ｖａｌ－Ｙ（Ｙはアミノ酸又はアミノ酸誘導体を表す）、γ－Ｇｌｕ－Ａｌａ、γ－Ｇｌｕ－Ｇｌｙ、γ－Ｇｌｕ－Ｃｙｓ、γ－Ｇｌｕ－Ｍｅｔ、γ－Ｇｌｕ－Ｔｈｒ、γ－Ｇｌｕ－Ｖａｌ、γ－Ｇｌｕ－Ｏｒｎ、Ａｓｐ－Ｇｌｙ、Ｃｙｓ－Ｇｌｙ、Ｃｙｓ－Ｍｅｔ、Ｇｌｕ－Ｃｙｓ、Ｇｌｙ－Ｃｙｓ、Ｌｅｕ－Ａｓｐ、γ－Ｇｌｕ－Ｍｅｔ（Ｏ）、γ－Ｇｌｕ－γ－Ｇｌｕ－Ｖａｌ、γ－Ｇｌｕ－Ｖａｌ－ＮＨ2、γ－Ｇｌｕ－Ｖａｌ－ｏｌ、γ－Ｇｌｕ－Ｓｅｒ、γ－Ｇｌｕ－Ｔａｕ、γ－Ｇｌｕ－Ｃｙｓ（Ｓ－Ｍｅ）（Ｏ）、γ－Ｇｌｕ－Ｌｅｕ、γ－Ｇｌｕ－Ｉｌｅ、γ－Ｇｌｕ－ｔ－Ｌｅｕおよびγ－Ｇｌｕ－Ｃｙｓ（Ｓ－Ｍｅ）等のペプチド等を下痢の予防又は治療剤の有効成分とする。
PCT/JP2008/058328 2007-05-08 2008-05-01 下痢の予防又は治療剤 WO2008139947A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08752258.7A EP2156846B1 (en) 2007-05-08 2008-05-01 Prophylactic or therapeutic agent for diarrhea
JP2009514106A JP5321452B2 (ja) 2007-05-08 2008-05-01 下痢の予防又は治療剤
ES08752258.7T ES2499015T3 (es) 2007-05-08 2008-05-01 Agente profiláctico o terapéutico para la diarrea
US12/613,727 US20100105864A1 (en) 2007-05-08 2009-11-06 Prophylactic or therapeutic agent for diarrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007123765 2007-05-08
JP2007-123765 2007-05-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/613,727 Continuation US20100105864A1 (en) 2007-05-08 2009-11-06 Prophylactic or therapeutic agent for diarrhea

Publications (1)

Publication Number Publication Date
WO2008139947A1 true WO2008139947A1 (ja) 2008-11-20

Family

ID=40002155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058328 WO2008139947A1 (ja) 2007-05-08 2008-05-01 下痢の予防又は治療剤

Country Status (5)

Country Link
US (1) US20100105864A1 (ja)
EP (1) EP2156846B1 (ja)
JP (2) JP5321452B2 (ja)
ES (1) ES2499015T3 (ja)
WO (1) WO2008139947A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107660A1 (ja) 2008-02-25 2009-09-03 味の素株式会社 糖尿病又は肥満病の予防又は治療剤
WO2009119554A1 (ja) 2008-03-24 2009-10-01 味の素株式会社 消化管の重炭酸分泌促進剤
WO2013051685A1 (ja) 2011-10-07 2013-04-11 味の素株式会社 変異型γ－グルタミルトランスフェラーゼ、及び、γ-グルタミルバリルグリシン又はその塩の製造法
US8454978B2 (en) * 2008-04-17 2013-06-04 Ajinomoto Co., Inc. Immunostimulating agent
WO2015115612A1 (ja) 2014-01-31 2015-08-06 味の素株式会社 変異型グルタミン酸－システインリガーゼ、及び、γ－グルタミルバリルグリシンの製造法
US9253997B2 (en) 2010-03-04 2016-02-09 Ajinomoto Co., Inc. Alkylamine derivative
EP3530749A1 (en) 2018-02-27 2019-08-28 Ajinomoto Co., Inc. Glutathione synthetase mutant and method for producing gamma-glu-val-gly
US11788109B2 (en) 2015-09-04 2023-10-17 Ajinomoto Co., Inc. Microorganism and method for producing gamma-glutamyl-valyl-glycine

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2299271B9 (en) * 2005-11-09 2014-02-26 Ajinomoto Co., Inc. Kokumi-imparting compositions
US8420144B2 (en) * 2005-11-09 2013-04-16 Ajinomoto Co., Inc. Kokumi-imparting agent, method of using, and compositions containing same
EP1945201B1 (en) * 2005-11-09 2011-09-28 Ajinomoto Co., Inc. Calcium receptor activator
RU2536934C2 (ru) 2009-04-01 2014-12-27 Адзиномото Ко., Инк. Применение пептидов для придания кокуми
PH12012501338A1 (en) 2009-12-28 2016-05-20 Ajinomoto Kk Flavor-enriching agent
JP5807843B2 (ja) 2009-12-28 2015-11-10 味の素株式会社 ランチオニン誘導体
JP6690529B2 (ja) 2014-03-05 2020-04-28 味の素株式会社 γ−グルタミルバリン合成酵素、及び、γ−グルタミルバリルグリシンの製造法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035983A1 (en) * 1999-11-16 2001-05-25 Karolinska Innovations Ab Pharmaceutical composition for treatment of diarrhea
WO2007027548A2 (en) * 2005-09-02 2007-03-08 Amgen Inc. Methods of modulating intestinal fluid balance
WO2007055393A1 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Kokumi-imparting agent
WO2007055388A2 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Calcium receptor activator

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1553078A1 (en) * 1994-10-21 2005-07-13 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
ATE352537T1 (de) * 1996-05-01 2007-02-15 Nps Pharma Inc Verbindungen, die auf anorganische ionen- rezeptoren wirken
EP1572113B1 (en) * 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
US20040204577A1 (en) * 2003-01-24 2004-10-14 Ajinomoto Co., Inc. Novel peptide-forming enzyme gene
US7754677B2 (en) * 2003-12-05 2010-07-13 Hill's Pet Nutrition, Inc. Composition and method for reducing diarrhea in a mammal
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
CA2630860A1 (en) * 2005-11-25 2007-05-31 Galapagos Sas Urea derivatives useful as calcium receptor modulators
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
CA2686795C (en) * 2007-05-08 2015-11-24 Ajinomoto Co., Inc. Low-fat food comprising a calcium receptor
AU2008249288C1 (en) * 2007-05-08 2014-11-13 Ajinomoto Co., Inc. Sweetener
CA2692598A1 (en) * 2007-07-10 2009-01-15 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
JPWO2009107660A1 (ja) * 2008-02-25 2011-07-07 味の素株式会社 糖尿病又は肥満病の予防又は治療剤
WO2009119554A1 (ja) * 2008-03-24 2009-10-01 味の素株式会社 消化管の重炭酸分泌促進剤
EP2345636B1 (en) * 2008-10-03 2016-03-30 Ajinomoto Co., Inc. Casr agonist

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035983A1 (en) * 1999-11-16 2001-05-25 Karolinska Innovations Ab Pharmaceutical composition for treatment of diarrhea
WO2007027548A2 (en) * 2005-09-02 2007-03-08 Amgen Inc. Methods of modulating intestinal fluid balance
WO2007055393A1 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Kokumi-imparting agent
WO2007055388A2 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Calcium receptor activator

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEIBEL J. ET AL.: "Calcium-sensing receptor abrogates secretagogue-induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 103, no. 25, 2006, pages 9390 - 9397, XP001539876 *
WANG M. ET AL.: "Activation of Family C G-protein-coupled Receptors by the Tripeptide Glutathione", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 13, 31 March 2006 (2006-03-31), pages 8864 - 8870, XP008123658 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107660A1 (ja) 2008-02-25 2009-09-03 味の素株式会社 糖尿病又は肥満病の予防又は治療剤
WO2009119554A1 (ja) 2008-03-24 2009-10-01 味の素株式会社 消化管の重炭酸分泌促進剤
US8454978B2 (en) * 2008-04-17 2013-06-04 Ajinomoto Co., Inc. Immunostimulating agent
US9561216B2 (en) 2010-03-04 2017-02-07 Ea Pharma Co., Ltd. Alkylamine derivative
US9253997B2 (en) 2010-03-04 2016-02-09 Ajinomoto Co., Inc. Alkylamine derivative
USRE49569E1 (en) 2010-03-04 2023-07-04 Ea Pharma Co., Ltd. Alkylamine derivative
WO2013051685A1 (ja) 2011-10-07 2013-04-11 味の素株式会社 変異型γ－グルタミルトランスフェラーゼ、及び、γ-グルタミルバリルグリシン又はその塩の製造法
US9580696B2 (en) 2011-10-07 2017-02-28 Ajinomoto Co., Inc. Method for producing γ-glutamylvalylglycine or a salt thereof
US9677106B2 (en) 2011-10-07 2017-06-13 Ajinomoto Co., Inc. Method for producing gamma-glutamylvalylglycine or a salt thereof
WO2015115612A1 (ja) 2014-01-31 2015-08-06 味の素株式会社 変異型グルタミン酸－システインリガーゼ、及び、γ－グルタミルバリルグリシンの製造法
US11788109B2 (en) 2015-09-04 2023-10-17 Ajinomoto Co., Inc. Microorganism and method for producing gamma-glutamyl-valyl-glycine
EP3530749A1 (en) 2018-02-27 2019-08-28 Ajinomoto Co., Inc. Glutathione synthetase mutant and method for producing gamma-glu-val-gly
US11142755B2 (en) 2018-02-27 2021-10-12 Ajinomoto Co., Inc. Mutant glutathione synthetase and method for producing gamma-glutamyl-valyl-glycine

Also Published As

Publication number Publication date
ES2499015T3 (es) 2014-09-26
JP5321452B2 (ja) 2013-10-23
JPWO2008139947A1 (ja) 2010-08-05
US20100105864A1 (en) 2010-04-29
JP2013209402A (ja) 2013-10-10
JP5716791B2 (ja) 2015-05-13
EP2156846A4 (en) 2012-03-07
EP2156846B1 (en) 2014-08-13
EP2156846A1 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
WO2008139947A1 (ja) 下痢の予防又は治療剤
WO2008139945A1 (ja) 低脂肪食品
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
WO2006131737A3 (en) Method and composition for treating inflammatory disorders
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2005072740A3 (en) Anorectic compounds
WO2006015943A3 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2007056073A3 (en) Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
WO2007042468A3 (de) Aerosolformulierung für die inhalation von betaagonisten
WO2009078447A1 (ja) 抗ノロウイルス剤、抗インフルエンザウイルス剤、およびこれらを用いた抗ウイルス処理方法
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2005089718A3 (en) Pharmaceutical compositions
WO2008084698A1 (ja) タクロリムス徐放性医薬組成物
WO2008020056A3 (de) Aerosolformulierung enthaltend betaagonisten und steroide
DK1572153T3 (da) Fremstilling af sterile vandige suspensioner, som omfatter mikroniserede krystallinske virksomme stoffer til inhalering
WO2010070449A3 (en) Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2007063702A3 (en) Iminopropene compound and use thereof
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2005065639A3 (en) Novel pharmaceutical compositions
NO20044132L (no) Legemidler som inneholder aktive ingredienser som senker kolesterolnivaet med tidsforsinket frigjoring av det aktive middelet
WO2003024933A1 (fr) Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752258

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009514106

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008752258

Country of ref document: EP